| Sarah Acland, MD | |
|
6200 Crestwood Sta, Suite A, Crestwood, KY 40014-7418 | |
| (502) 243-2622 | |
| (502) 243-2692 |
| Full Name | Sarah Acland |
|---|---|
| Gender | Female |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | 6200 Crestwood Sta, Crestwood, Kentucky |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750489944 | NPI | - | NPPES |
| 161426 | Other | VALUEOPTIONS | |
| 19199 | Other | KY | MEDICAL LICENSE |
| 000000609057 | Other | ANTHEM BCBS PIN | |
| 2163307 | Other | COMPSYCH | |
| KY19199 | Other | KY MEDICAL LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 19199 (Kentucky) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Sarah Acland, MD 6200 Crestwood Sta Ste A, Crestwood, KY 40014-7418 Ph: (502) 243-2622 | Sarah Acland, MD 6200 Crestwood Sta, Suite A, Crestwood, KY 40014-7418 Ph: (502) 243-2622 |
News Archive
An international, open-label Phase 3 study, co-led by Susanna McColley, MD, from Ann & Robert H. Lurie Children's Hospital of Chicago, found that a regimen of three drugs (elexacaftor/tezacaftor/ivacaftor) that targets the genetic cause of cystic fibrosis was safe and effective in 6-11-year-olds with at least one copy of F508del mutation in the CFTR gene, which is estimated to represent almost 90 percent of the cystic fibrosis population in the United States.
Scientists have uncovered molecules released by invasive skin cancer that reprogram healthy immune cells to help the cancer to spread.
Advanced materials are revolutionizing our daily lives — from clothing to clinics to … cattle? A nanomaterial-based bone regeneration technology developed at the University of Arkansas at Little Rock helped save a valuable animal's life. In the future, this technology could help people suffering from a variety of severe injuries and ailments.
SDI (Strategic Diagnostics Inc.), a leading provider of biotechnology-based products and services for a broad range of life science, food safety, and industrial applications, today announced it has been selected again by Science Applications International Corporation - Frederick (SAIC-F) to develop monoclonal antibodies for the National Cancer Institute's "Clinical Proteomic Technologies for Cancer" initiative (CPTC: http://proteomics.cancer.gov).
Mary-Claire Hanlon, a Psychology Honours student at the University of Newcastle under the supervision of Dr Frini Karayanidis and Associate Professor Ulrich Schall, is recruiting participants for the study investigating the role of sound and dopaminergic mechanisms (brain chemicals) in people with ADHD.
› Verified 5 days ago
Dr. James B Tabler, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 6225 W. Hwy 146, Ste 1, Crestwood, KY 40014 Phone: 502-822-3499 Fax: 502-822-1564 |